We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds
Read MoreHide Full Article
Pfizer (PFE - Free Report) announced positive top-line data from a phase III study evaluating the co-administration of its newly approved 20-valent pneumococcal conjugate vaccine, Prevnar-20 with it and partner BioNTech’s (BNTX - Free Report) mRNA-based COVID-19 vaccine at the same time in adults 65 years of age or older.
The study also evaluated the safety and immunogenicity of Prevnar 20 and COVID vaccine each given with a placebo. Data from the study demonstrated similar responses elicited by Prevnar 20 for all 20 serotypes whether given with a dose of COVID-19 vaccine or with placebo. The responses generated by a booster shot of the COVID-19 vaccine were also similar when given with Prevnar 20 or a placebo
The safety profile for the co-administration of Prevnar 20/COVID-19 vaccine booster dose was similar to that observed with the booster dose.
The data clearly shows that the COVID-19 and pneumococcal vaccines can be given at the same time, thereby reducing the number of patient visits to the doctor. The study evaluating the coadministration of Prevnar 20 along with a booster dose of the COVID-19 vaccine was initiated in May last year.
Pfizer’s stock has risen 60.2% in the past year compared with an increase of 21.4% for the industry.
Image Source: Zacks Investment Research
Prevnar-20 was approved in the United States in June 2021 while it is under review in the EU.
Pfizer and BioNTech’s COVID-19 vaccine was developed in record time and is now approved for emergency/temporary use in several countries worldwide and fully approved in the United States. Pfizer and BioNTech’s vaccine was approved for younger patients (5-17 years) while a booster vaccine dose was also approved in the United States in 2021.
Pfizer and BioNTech’s COVID-19 vaccine has become a key contributor to the top line. In the first nine months of 2021, the vaccine contributed $24.3 billion to Pfizer’s global sales. The pharma giant expects 2021 Comirnaty revenues to be $36.0 billion. The fourth-quarter and full-year 2021 results are expected to be announced on Feb 8.
Some other top-ranked stock large drug/biotech stocks are AbbVie (ABBV - Free Report) and Regeneron (REGN - Free Report) , both with a Zacks Rank of 2 (Buy).
AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days.
AbbVie’s earnings performance has been strong with the company exceeding earnings expectations in each of the last four quarters. AbbVie has a four-quarter earnings surprise of 3.02%, on average.
Regeneron’s 2022 earnings per share estimates have risen from $46.98 to $48.06 over the past 60 days. REGN’s stock is up 21.9% year over year.
Regeneron’s earnings performance has been strong with the company exceeding earnings expectations in each of the last four quarters. Regeneron has a four-quarter earnings surprise of 28.93%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds
Pfizer (PFE - Free Report) announced positive top-line data from a phase III study evaluating the co-administration of its newly approved 20-valent pneumococcal conjugate vaccine, Prevnar-20 with it and partner BioNTech’s (BNTX - Free Report) mRNA-based COVID-19 vaccine at the same time in adults 65 years of age or older.
The study also evaluated the safety and immunogenicity of Prevnar 20 and COVID vaccine each given with a placebo. Data from the study demonstrated similar responses elicited by Prevnar 20 for all 20 serotypes whether given with a dose of COVID-19 vaccine or with placebo. The responses generated by a booster shot of the COVID-19 vaccine were also similar when given with Prevnar 20 or a placebo
The safety profile for the co-administration of Prevnar 20/COVID-19 vaccine booster dose was similar to that observed with the booster dose.
The data clearly shows that the COVID-19 and pneumococcal vaccines can be given at the same time, thereby reducing the number of patient visits to the doctor. The study evaluating the coadministration of Prevnar 20 along with a booster dose of the COVID-19 vaccine was initiated in May last year.
Pfizer’s stock has risen 60.2% in the past year compared with an increase of 21.4% for the industry.
Prevnar-20 was approved in the United States in June 2021 while it is under review in the EU.
Pfizer and BioNTech’s COVID-19 vaccine was developed in record time and is now approved for emergency/temporary use in several countries worldwide and fully approved in the United States. Pfizer and BioNTech’s vaccine was approved for younger patients (5-17 years) while a booster vaccine dose was also approved in the United States in 2021.
Pfizer and BioNTech’s COVID-19 vaccine has become a key contributor to the top line. In the first nine months of 2021, the vaccine contributed $24.3 billion to Pfizer’s global sales. The pharma giant expects 2021 Comirnaty revenues to be $36.0 billion. The fourth-quarter and full-year 2021 results are expected to be announced on Feb 8.
Pfizer sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Some other top-ranked stock large drug/biotech stocks are AbbVie (ABBV - Free Report) and Regeneron (REGN - Free Report) , both with a Zacks Rank of 2 (Buy).
AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days.
AbbVie’s earnings performance has been strong with the company exceeding earnings expectations in each of the last four quarters. AbbVie has a four-quarter earnings surprise of 3.02%, on average.
Regeneron’s 2022 earnings per share estimates have risen from $46.98 to $48.06 over the past 60 days. REGN’s stock is up 21.9% year over year.
Regeneron’s earnings performance has been strong with the company exceeding earnings expectations in each of the last four quarters. Regeneron has a four-quarter earnings surprise of 28.93%, on average.